Growth momentum Recent Q3 2026 core revenue growth of 26% year over year and updated guidance signaling ~15% H2 2026 growth present a sales opportunity to position MaxCyte’ s enabling platform as a scalable solution for expanding cell therapy programs and CRO partnerships.

Strategic leadership New Chief Corporate Development Officer appointment suggests a focus on strategic partnerships, alliances, and corporate development opportunities—a signal for targeted outreach to potential collaborators, licensors, and integration partners.

Off-target precision Launch of CHANGE-seq-BE and ONE-seq-BE off-target nomination assays via SeQure service demonstrates advanced validation capabilities that can be sold to gene-editing programs prioritizing safety and regulatory-ready programs.

Regulatory readiness combined with 25+ years in cell engineering and regulatory guidance support, MaxCyte offers a compelling value proposition for biotechs seeking to de-risk therapy development and accelerate regulatory submissions.

Expansion potential Recognized as a pioneer in cell and gene therapies and ongoing platform enhancements indicate opportunities to upsell expanded use across diverse cell types and payloads, including partnerships with larger biopharma and contract development manufacturers.